A Pennsylvania Judge has been assigned to oversee a growing number of lawsuits targeting the weight loss drug, Ozempic. The legal action has been instigated against pharmaceutical giants Eli Lilly and Novo Nordisk, with lawyers collaboratively filing 55 cases on their clients’ behalf. The issue was brought before the U.S. Judicial Panel on Multidistrict Litigation last Friday, leading to a decision for the cases to be coordinated into multidistrict litigation. Details of this ongoing issue are further explained in this article from the New York Law Journal.
Ozempic is among several drugs raising legal concerns, with Mounjaro also listed in the coordinated multidistrict litigation. It remains to be seen what the outcomes of these hearings will be, and the potential effects on these pharmaceutical corporations. Legal professionals worldwide are closely monitoring the developments of these cases, given the high stakes for both patients and the drug manufacturers.